Recently, the IPI‐based immune prognostic model based on eight genes including IL12A had independent prognostic significance in DLBCL patients, which provided an immunological perspective for elucidating the tumor progression mechanism of DLBCL, and were also useful for DLBCL immunotherapy.74 This evidence concerns the gene IL12A and neoplasm.